FDA Proposes Sliding-Scale Paradigm For Obesity Device Trials
This article was originally published in The Gray Sheet
Higher-risk devices, based on feasibility trial adverse event rates, would be matched to steeper effectiveness targets in pivotal studies for weight-loss under a plan outlined by the agency.
You may also be interested in...
Approved as a long-term treatment option for obese patients with a body-mass index of 35 to 55, Aspire Bariatrics is positioning its AspireAssist device as a less-invasive alternative to bariatric surgery in the population of morbidly obese individuals who are most often recommended for a procedure. The system includes an endoscopically implanted tube and a port used by the patient to drain contents of the stomach and reduce calories absorbed.
Nearly half of the world’s adult population will be overweight or obese by 2030 and obesity is tied to more than 40 diseases. Enterprising companies are heeding the call with increasingly less invasive weight loss devices, while an amenable regulatory environment means the marketplace will welcome some of these innovations in 2015.
The agency approved EnteroMedics’ Maestro neuromodulator to treat obesity despite the device not meeting endpoints in its pivotal trial. The agency relied in part on a survey that found obese patients willing to take more risks in exchange for weight loss.